ILC Therapeutics

ILC Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $548K
Latest Deal Amount
  • Investors
  • 4

ILC Therapeutics General Information

Description

Operator a biotechnology drug research platform intended to develop modernized and better drug therapy. The company's platform has been exploring the differences in immune response between the alpha-interferon sub-types with a view to identifying those that can be optimized in drug therapy, enabling health institutions and related medical centers with a drug therapy which can unlock the therapeutic potential of interferon.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Biocity Scotland
  • Bo'ness Road, Newhouse, Lanarkshire
  • Glasgow ML1 5UH
  • Scotland, United Kingdom
+44 07403 000000

ILC Therapeutics Timeline

2017201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ILC Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 15-Jan-2020 $548K 00.00 00.000 Completed Generating Revenue
6. Accelerator/Incubator 15-Nov-2019 000.00 00.000 Completed Generating Revenue
5. Later Stage VC 09-Jul-2018 00000 00.000 00.000 Completed Generating Revenue
4. Later Stage VC 14-Dec-2017 00000 00000 00000 Completed Generating Revenue
3. Grant 27-Jan-2017 00000 Completed Generating Revenue
2. Early Stage VC 04-Jan-2017 $310K $700K 00.000 Completed Generating Revenue
1. Seed Round 30-Jul-2015 $390K $390K 00000 Completed Startup

ILC Therapeutics Cap Table

To view ILC Therapeutics‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A Ordinary 00,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary A 00,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary A 00,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary A 00,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary A 27,213 $1.307218 $11.53 $11.53 1x $11.53 9.26%
Ordinary A 5,555 $1.307218 $2.35 $2.35 1x $2.35 1.89%

ILC Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
William Stimson Ph.D Founder, Chief Scientific Officer and Board Member
Martin Ramsay Director, Finance & Board Member
Magnus Nicolson Chairman

1 Former Executive

ILC Therapeutics Board Members (6)

To view ILC Therapeutics‘s full board member team, request access »
Name Representing Role Since
Hazel Allen ILC Therapeutics Board Member 000 0000
Kevin Grainger EOS Technology Investment Syndicate Board Member 000 0000
Magnus Nicolson Self Chairman 000 0000
Martin Ramsay ILC Therapeutics Director, Finance & Board Member 000 0000

2 Former Board Members

ILC Therapeutics Investors (4)

To view ILC Therapeutics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioCity Accelerator/Incubator Minority 000 0000 000000 0
Industrial Biotechnology Innovation Centre Government 000 0000 000000 0
EOS Technology Investment Syndicate Angel Group Minority 000 0000 000000 0
Scottish Enterprise Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial